CLINICAL TRIALS PROFILE FOR ACITRETIN
✉ Email this page to a colleague
All Clinical Trials for ACITRETIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002143 ↗ | Treatment of Psoriasis Using Acitretin in HIV-Positive Patients | Completed | Hoffmann-La Roche | Phase 3 | 1969-12-31 | To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. |
| NCT00003611 ↗ | Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation | Completed | National Cancer Institute (NCI) | N/A | 2000-05-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of acitretin may be an effective way to prevent the recurrence or further development of skin cancer. PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin cancers in patients with at least two previously treated skin cancers who have undergone organ transplantation. |
| NCT00003611 ↗ | Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation | Completed | Alliance for Clinical Trials in Oncology | N/A | 2000-05-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of acitretin may be an effective way to prevent the recurrence or further development of skin cancer. PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin cancers in patients with at least two previously treated skin cancers who have undergone organ transplantation. |
| NCT00156247 ↗ | Acitretin and Etanercept in Psoriasis | Completed | Connetics Corp. | Phase 2 | 2005-09-01 | To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults. |
| NCT00156247 ↗ | Acitretin and Etanercept in Psoriasis | Completed | University of Medicine and Dentistry of New Jersey | Phase 2 | 2005-09-01 | To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACITRETIN
Condition Name
Clinical Trial Locations for ACITRETIN
Trials by Country
Clinical Trial Progress for ACITRETIN
Clinical Trial Phase
Clinical Trial Sponsors for ACITRETIN
Sponsor Name
